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INTRODUCTION 
PCNL is considered to be the standard procedure in patients with 
large renal calculus. The essential step in standard percutaneous 
nephrolithotomy (PCNL) procedure is placement of a percutaneous 
nephrostomy tube for drainage. On the other hand, in recent years, the 
procedure has been reformed to one called as 'tubeless' PCNL in which a 
double-J stent without nephrostomy tube is placed for internal drainage.  
 Urinary stones are defined as the poly crystalline aggregates 
composed of variable amounts of crystal and organic matrix components. 
The most common stone types are calcium oxalate, calcium phosphate, 
uric acid, struvite i.e., magnesium ammonium phosphate and cysteine. 
    Urinary stone disease is one of those diseases well-known to affect 
humans ever since olden times.  
There has been deviation in the occurrence of stone disease from 
the lower to upper urinary tract. The occurrence of stone disease is 2 to 3 
times more in young males than females in the past nevertheless this 
difference is now declining.  
The estimated prevalence of renal stone disease is 1% to 5%. 
Soucie et al proposed that the prevalence of stone disease is 10% in males 
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and 4% in females1. Whites are commonly affected than Asians and Afro-
Americans. 
The incidence of stone disease is highest in fourth to sixth decades. 
Hot arid climate, obesity and sedentary lifestyle predispose to stone 
formation. 
Hippocrates had described the renal colic symptoms as follows:  
 “An acute pain is felt in the kidney, the loins, the flank and the 
testis of the affected side. The patient passes urine frequently. Gradually 
the urine is suppressed. With the urine, the sand is passed.” 
There had been a vast progress in the evaluation, imaging and 
management of this disease. Initially the management procedures had 
significant morbidity and sometimes mortality.  
With advances in surgical techniques, the mortality has reduced 
considerably. PCNL had improved reasonably over the last twenty years 
as a result of technical advancements and perfections in surgical skill for 
doing PCNL. A milestone in the history of PCNL is the introduction and 
development of the ‘tubeless PCNL’ which is now been proposed to have 
a comparatively lesser morbidity rates than the standard procedure. The 
purpose of this study is to analyse the evidence -based literature regarding 
the ‘nephrostomy-free’ or ‘tubeless’ PCNL and to assess the safety, 
efficacy, possibility, and benefits of tubeless PCNL over standard PCNL. 
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AIM AND OBJECTIVE 
Primary Objective 
To systematically review and compare tubeless percutaneous 
nephrolithotomy (PCNL) with standard PCNL  
• Safety 
• Effectiveness 
•  Feasibility 
• Postoperative pain 
•  Morbidity 
• Hospital stay 
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REVIEW OF LITERATURE 
Urinary stone disease- A History 
Humans were being affected by urinary stone disease since time 
immemorial. The oldest renal stone documented in writings was the one 
founded in an Egyptian mummy in a tomb dating to roughly 
4400BC2.This was documented in literature by Shattock. But then only in 
the 19th century, all urinary stones known today were identified, defined 
and named.  
Even though stone disease had been studied by physicians and 
surgeons for thousands of years, the major part of the evolution in the 
stone analysis took place in the last two centuries.  
The management of renal calculus is largely divided into medical 
and surgical. 
Medical management is done in asymptomatic patients with 
minimal stone burden. It also helps to prevent recurrence of certain types 
of stones. Initially medical management was not very successful because 
of insufficient knowledge regarding the pathogenesis of stone formation. 
With betterment in knowledge regarding the pathogenesis and 
technical advancements, medical management has improved a lot and 
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now plays an important role in the renal stone management. Besides 
treatment of the stone disease, there is an extremely important necessity 
to tackle the recurrence of stone formation. 
Surgical management continues to be the mainstay of treatment in 
numerous patients. Surgical management of stone disease has evolved 
over many centuries to the present state.  
Prehistoric literatures state that surgical management was 
attempted enthusiastically despite increased incidence of morbidity and at 
times mortality. 
The technique of removal of urinary tract stones done in Egypt had 
been described by Eric Riches as follows: 
 “The urethra was dilated by a wooden or cartilaginous cannula as 
thick as the thumb pushed in with great force alternating with blowing 
down the urethra; the stone was pressed down into the perineum by the 
fingers in the rectum until it could be reached from the urethra or sucked 
out by the mouth3”. 
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PATHOPHYSIOLOGY 
The most common type of stone is of the calcium variety. The 
etiology of stone formation is probably multifactorial. A complex cascade 
of events occurs as the glomerular filtrate traverses the nephron and this 
result in stone formation. To start with the urine becomes supersaturated 
with the respective stone forming salts. But this supersaturation alone is 
not enough for the crystallisation to occur as there are urinary inhibitors 
which promptly prevent aggregation of crystals whenever there is 
supersaturation of stone forming salts.   
Nephrocalcin, Uropontin, and Tamm-Horsfall Protein are 
important inhibitors of crystal nucleation, growth, or aggregation.  
In case of the commonest stone type i.e., calcium stones, both the 
urinary calcium and oxalate play an important role in the supersaturation 
and formation of calcium oxalate crystals. Subepithelial plaques 
composed of calcium apatite form initially and they act as a platform on 
which calcium oxalate stones develop. The noncrystalline component of 
stones is called matrix. This matrix constitutes mucoproteins, proteins, 
carbohydrates, and urinary inhibitors.  
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MEDICAL MANAGEMENT 
Medical management of stone disease had evolved over centuries 
to the contemporary status. Improved knowledge on the subject of 
pathogenesis of stone formation had facilitated the improvement. 
Therefore nowadays some form of medical treatment is being 
suggested to the patients with renal calculus regardless of the aetiology of 
the disease. 
ROLE OF FLUID INTAKE 
Patients are advised to increase their fluid intake accordingly that 
their ultimate urine output at the end of the day is not less than 2 litres. 
This sort of physiologically induced diuresis prevents stagnation of urine 
thereby reducing the formation of stones. This also helps by altering the 
specific gravity of urine i.e., by producing dilute urine and thereby 
preventing supersaturation of various components responsible for 
formation of stone5. 
Hosking and associates defined a phenomenon named “stone clinic 
effect” in single stone formers according to which increase in fluid intake 
in the above said patients results in reduced recurrence of the same4. 
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It has been observed that the hardness of drinking water has no role 
in stone formation.  
Carbonated drinks especially the ones with citric acid as acidifier 
have been found to protect from formation of stones5. 
A number of studies have concluded that the amount of fluid taken 
is important than the type of fluid. Therefore it is desirable to take a 
minimum of 3000ml of fluid a day so as to maintain an output of 2500ml 
a day.     
ROLE OF DIET 
Latest studies shed light on the role of diet in stone formation. 
Dietary modifications play a significant role in preventing stone 
formation. Diet has a significant role in the increasing incidence of stone 
disease in females.  
Animal protein intake in large amounts predispose to stone 
formation. Higher incidence of stone disease in northern and western 
parts of India compared to eastern and southern parts has been attributed 
to increased intake of animal protein in the above mentioned regions. 
Excess excretion of calcium, uric acid and oxalate in those with increased 
animal protein consumption predispose to stone formation. 
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Restriction of dietary sodium intake is one more essential way of 
decreasing stone recurrence6. Basis of this concept is that high sodium in 
the diet results in increased levels of sodium and calcium in urine and 
also increases its pH level whereas it decreases the citrate level in urine 
thereby facilitating crystallisation of calcium in urine. Therefore 
moderate sodium restriction aids to prevent recurrence7. 
Modest intake of calcium is always recommended in patients with 
calcium stone, meaning severe restriction of dietary calcium results in 
increased oxalate absorption thereby causing calcium oxalate 
supersaturationin urine. Hence calcium intake in moderate amounts is 
recommended8. Calcium citrate supplements are more stone friendly than 
other calcium compounds and hence preferred8. 
Oxalate stone formers are advised to avoid oxalate in diet and 
restrict their ascorbic acid intake to less than 2 grams per day.  
Selective medical treatment is very effective and hence preferred to 
prevent recurrence of certain types of stones. Use of citrate in 
hypocitraturic patients, alkalisation of urine to increase pH, use of 
mercaptopurine, D-penicillamine or captopril to increase the solubility of 
cysteine, use of urease inhibitor acetohydroxamic acid in stones of 
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infective etiology and avoidance of drugs inducing stone formation are a 
few selective medical treatments available. 
Incidence of stone diseases is higher in persons with increased 
body mass index. This tendency is higher in females than males. Various 
studies have revealed that metabolic syndrome predisposes to stone 
formation9. 
SURGICAL MANAGEMENT 
Surgery for stone disease is largely into open procedures and 
endourological management.  
OPEN PROCEDURE 
 The alleged first attempt of stone removal in a patient is the story 
of French archer of Bagnolet. The surgeons then claimed removal of a 
renal calculus in a condemned individual who was offered freedom in 
return if he admits to undergo the crude procedure. That man withstood 
the procedure and survived following stone removal and hence he was 
freed as per the agreement in 1474.  As there are no first hand records, the 
authenticity of this event is doubtful. 
The very first provable event of renal surgery was in 1550 when 
Cardan of Milan operated on a teenage girl with lumbar abscess and 
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removed 18 calculi. At that time, the consensus was to operate in those 
patients with infections in kidneys due to calculus. 
In 1734, Lafite drained an abscess bulging through the loin but the 
persistent drainage of pus for days together made him to extend the 
original incision and he ended up removing two calculi. He also treated a 
patient with urinary fistula due to renal calculus. He suggested that 
treatment of underlying stone disease will relieve the patient of his 
symptoms and also removal of the renal stones will save the patient from 
undergoing multiple procedures. 
In 1872, William Ingalls explored the persistent fistulous tract with 
a forceps and extracted a calculus from the kidney and this being the very 
first nephrolithotomy in Boston, USA10. 
    In 1880, Henry Morris performed the first nephrolithotomy in England 
and removed a mulberry calculus. 
With advances in technology, the procedure became more refined 
and the hemorrhagic complication was brought to control with usage of 
modified incisions.In 1879, Heineke simplified the pyelotomy incision 
that became popular thereafter. The main disadvantage of this incision 
was that it could not be extended to extract larger calculi. 
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More efforts were made to reduce the complications which led to 
the discovery of an avascular plane immediately posterior to the convex 
border of the kidney described by Josef Hyrtl (1882) and Max Brödel 
(1902). This plane was termed as “Brödel’s bloodless line or white line” 
(Schultheiss and associates, 2000)11.  
Despite the improvements in the techniques complications 
occurred. Zuckerkandl introduced the inferior pyelolithotomy incision in 
which the original pyelotomy incision was extended into the lower pole. 
Another discovery was a V incision into the poles. Other methods to 
control hemorrhage were hilar compression to occlude the vessels and a 
few innovative surgical techniques.   
Czerny in 1887described a new suturing technique to control 
hemorrhage and it was claimed that it would significantly reduce the 
development of pyelocutaneous fistula.  
Guyon described the side effects of nephrectomy which was then 
the universally preferred treatment for calculus pyonephrosis especially 
for bilateral stone disease. During that time nephrectomy was considered 
to be a relatively easy procedure than stone extraction. 
Kummel in 1889 did a nephron sparing surgery, the first of its 
kind, for stone disease. Lower in 1913, recommended pyelolithotomy 
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over nephrolithotomy as the former method was comparatively safer and 
easier than the later. Murphy and colleagues conducted a study in 1972 
and proposed that there is no difference in the recurrence rate of stone 
disease following nephrolithotomy and pyelolithotomy. Henceforth 
pyelolithotomy became the preferred procedure. 
Dees and Fox demonstrated the removal of stones with the use of a 
coagulum made from the combination of fibrinogen and thrombin. This 
coagulum was introduced into the renal pelvis to make a cast of it. The 
risk of transmissible infection limited its use (Marshall, 1983). Fischer 
and associates in 1980 made use of cryoprecipitate to form coagulum as it 
is a rich source of fibrinogen. It was considered to be relatively safer and 
also it was easily available12. 
A breakthrough in the surgical management of stone disease was 
made by Gil Vernet in 1965 when he demonstrated the procedure called 
extended pyelolithotomy. Henceforth this   became the procedure of 
choice for patients with large and complex calculi. It is now widely used 
with acceptable minimal morbidity. Further advancements were made by 
combining this with nephrotomies by extending the incision in radial 
directions as and when required.      
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In 1968, Smith and Boyce recommended a method of approaching 
the kidney by making the incision through the bloodless field. This 
procedure was termed “Anatrophic Nephrolithotomy” as the procedure 
did not interfere with the parenchymal blood supply and hence no atrophy 
of parenchyma. This helped in successful removal of stone with 
restoration of calyceal anatomy and capsular integrity and thereby 
preserved renal function. But the morbidity related to the open procedures 
remained high and therefore the quest for a better approach continued. 
ENDOUROLOGY IN STONE DISEASE 
Arthur Smith defined endourology as “closed controlled 
manipulation within the genitourinary tract” 
        Wolf in 1979 introduced the first rigid endoscope for use in urology. 
Harold Hopkins developed the rod lens system and this led to the 
making of smaller ureteroscopes with more clarity and better working 
channels. 
Development of various energy sources to fragment calculi 
intracorporeally led to further developments in the field of endourology. 
Gain of access into the collecting system is the most important 
thing in the success of percutaneous nephrolithotomy. 
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The first therapeutic percutaneous nephrostomy was done by 
Thomas Hillier in 1865 (Bloom et al, 1989). 
PERCUTANEOUS NEPHROLITHOTOMY 
Technical advancements in endourology led to removal of renal 
calculus by percutaneous access for the first time by a Swedish Urologist 
named B. Johannson and a radiologist named Fernstrom in 1973 and 
subsequently in 197613. 
  The prototype was not a single step procedure as the one done now. 
Initially the procedure was done in several sittings over twenty days. First 
a percutaneous access tract to the pelvicalyceal system was established 
followed by introduction of a series of polypropylene semirigid dilators to 
progressively increase the size of the tract. These dilators were sterilised 
in steaming water before introduction. The final tract achieved was 20 Fr 
in size. Surgeons waited for the tract to mature and then extracted the 
calculus using a dormia basket. This very first procedure done to extract 
the renal calculus, though successful, was time consuming and tedious 
both for the patient and the doctor. 
Peter Alken, Michael Marberger, Wickham, Ronald A. Miller, 
Joseph Segura and Ralph Clayman pioneered in improving the methods 
of accessing the pelvicalyceal system14,15. 
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ACCESS TO THE COLLECING SYSTEM 
A sound knowledge on renal and perirenal anatomy is essential in 
gaining a safe and useful access to the pelvicalyceal system. Mobility of 
kidney with respiration and other normal variations in anatomy are some 
of the practical difficulties in obtaining an access. 
A complete knowledge about the relative location of both kidneys 
in relation to vertebral bodies and their orientation and tilt in relation to 
the spine are important for success. 
The risk of injury to the pleura and at times the lung while gaining 
access to the pelvicalyceal system has to be considered.  
There is a risk of injury to the colon in patients with retro renal 
colon. This is seen more commonly over the left side in thin individuals 
and also females.  
 The knowledge on anatomy of the collecting system is similarly 
important for successful access. The outmost part of the collecting system 
is the minor calyx. These minor calyces unite to form a major calyx that 
drains into the pelvis via infundibulum. It might be difficult in gaining 
access in patients with infundibular narrowing16. 
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Minor calyces draining only one papilla are called simple calyces 
while those draining multiple papillae are termed complex calyces. 
Complex calyces are commonly located in poles. The simple calyces are 
arranged in two rows and are located anteriorly or posteriorly16. 
Orientation of these calyces is important in determining the best 
access tract. The anteroposterior orientation also varies with the side. 
Two types of orientation have been described. In the Brodel type, 
the posterior calyces form an angle of 20° with the frontal plane, meaning 
that the posterior calyces are located laterally. In the Hodson type, the 
posterior calyces form an angle of 70° with the posterior plane, meaning 
that the posterior calyces are located medially.  
Brodel type of orientation is more common on the right side 
whereas the Hodson type is commonly seen on the left side. 
Vast studies conducted so far have revealed that posterior calyceal 
puncture made through the fornix is the ideal site for entry with minimal 
complications and hence is the favoured approach over others and the 
level of entry is decided by the position of the calculus within the kidney. 
Subcostal access is the safest place to enter17. 
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ACCESS ROUTES 
Gain of access into the upper tract collecting system is 
accomplished by both antegrade and retrograde approaches. 
 Indications for antegrade access include percutaneous 
endopyelotomy and endoureterotomy, nephrolithotomy, calyceal 
diverticula, hydrocalyces and antegrade ureteroscopic treatment of large 
ureteral stones, percutaneous resection of urothelial tumors and 
management of fungal bezoars. 
ANTEGRADE ACCESS 
Antegrade access is the standard approach followed for creating a 
percutaneous tract. A 21G or an 18G needle is inserted into the collecting 
system under either fluoroscopic or ultrasound guidance. And then a 
guide wire is introduced into the system. 
The tract is created by dilatation with rigid metal dilators 
introduced by Alken. These coaxial stainless steel dilators are passed over 
a rigid guide rod. The ball tip of the rod prevents overshooting of the 
dilators. This is particularly suitable for those with dense fibrous tissues 
surrounding the kidney. It is also more traumatic to the surrounding 
tissues. 
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Another choice is to use polyurethane semirigid Amplatz dilators. 
The dilatation is done in increments of 2 Fr size and the first dilator has to 
be removed before introducing the next higher sized dilator. The 
advantage of using these dilators is that they are less traumatic to the 
tissues. But the disadvantage is that there is a risk of haemorrhage each 
time the dilator is removed to insert the larger one18.  
Balloon dilators were introduced to overcome these difficulties but 
these are more expensive than the previous ones. Moreover these balloon 
dilators are less useful in densely scarred tissues.  
Of late single step dilatation techniques are performed using 
semirigid plastic dilator, rigid dilator with a sheath and balloon dilator 
with an expandable sheath19. Antegrade access is gained under 
fluoroscopic or ultrasonographic guidance20. But even today blind 
procedure is under practice. 
Pedersen invented the method of access under ultrasonographic 
guidance in 1974. Advantages of this method include use of portable 
machines and absence of radiation hazards. Disadvantages are operator 
dependability, difficulty in visualisation of the needle and also further 
monitoring is difficult.  
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Fluoroscopic method is the one commonly used. The two different 
techniques are “eye of the needle technique” and “triangulation 
technique”21. 
RETROGRADE ACCESS 
Retrograde access is very useful in obese individuals, anomalously 
located kidneys and hypermobile kidneys. Retrograde transurethral access 
is created by placement of a 5 Fr or a 6 Fr ureteric catheter followed by 
injection of contrast into the pelvicalyceal system in order to delineate 
and dilate the system. Now the guidewire is introduced into the system 
and is brought out via the percutaneous tract by grasping it with a 
nephroscope. 
An ureteroscope can also be used to create a tract by retrograde 
access. 
POSITIONING OF THE PATIENT 
Proper positioning of the patient for the procedure is very 
important. Prone position was first employed by Goodwin in 1955 to 
establish percutaneous access route. Prone position is the most favoured 
position as posterior calyceal puncture is easy to perform in this position. 
Also this position provides a wider area of access and a stable work 
surface. 
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Disadvantages of operating in this position include decrease in the 
cardiac index, diminished vital capacity if not padded properly, neuro 
musculoskeletal complications, ocular injury, rhabdomyolysis and 
difficulty in maintaining the airway22. 
          This difficulty was overcome by operating in supine position and 
this was recommended by Valdivia Uria in 1987. In this position anterior 
calyces were entered by a lateral or anterolateral approach23.  
Advantages of this position are the access sheath angle is 
horizontal and hence allows the fragments to get washed out easily 
because of reduced pressure inside the collecting system. As there is 
easier access to the urethra in this position no repositioning of the patient 
is required. 
Disadvantages are that this procedure is unfamiliar for the 
operating surgeons, and as well there is poor visualisation due to low 
collecting system pressure. And access to the upper pole is not easy in 
this position. 
          Other variants of this position are supine with same side elevation, 
supine with same side flank elevation, asymmetrical lithotomy position 
and flank position. 
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A nephrostomy tube is placed along with placement of a ureteral 
stent or catheter after successful fragmentation of stones and retrieval of 
the fragments. Nowadays tubeless procedure is done i.e., a nephrostomy 
tube is not placed in patients with complete clearance of stones24. Further 
advancement in the technique is performance of a totally tubeless 
procedure in which placement of a ureteric stent is also avoided25.  
 With the intention to avoid infectious complications pre-operative 
treatment of infections to make the urine sterile is always ideal. But then, 
it is not simple to achieve this goal in particular situations like anatomic 
abnormalities, recent hospitalisation, and presence of any infective foci in 
the body and in patients already with urinary catheter. These individuals 
require urine culture and treatment according to the sensitivity pattern.  
The protocol usually followed is to do a urine culture in patients 
with staghorn calculus and in those patients with a percutaneous drainage 
catheter. Rest of the patients require only urinalysis. Culture is indicated 
only if urinalysis is abnormal. Patients with positive cultures are treated 
with a complete course of antibiotics according to the sensitivity. 
Periprocedural antimicrobial prophylaxis is recommended in all patients 
undergoing percutaneous renal surgery by American Urological 
Association   (Wolf et al, 2008)26. 
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Nonrandomized trials show an infection rate of 35% to 40% if no 
antimicrobial prophylaxis is used compared with 0% to 17% if 
prophylaxis is used (Charton et al,1986; Darenkov et al, 1994)27. 
 The recommended prophylaxis is the use of first or second 
generation cephalosporins with either aminoglycosides in normal patients 
or aztreonam in patients with elevated renal parameters.  Furthermore 
metronidazole, clindamycin or a fluoroquinolone can be prescribed. 
Prophylactic antibiotics can be given for 24 hours.  
COMPLICATIONS OF PERCUTANEOUS 
NEPHROLITHOTOMY    
Although percutaneous nephrolithotomy is effective in the 
treatment of stone disease it is not without any complications. 
The most common complication of this procedure is hemorrhage. 
Blood transfusion is required in 0.5% to 4% of individuals undergoing 
percutaneous nephrostomy alone due to significant hemorrhage28.   6% - 
20% of   patients who undergo percutaneous nephrolithotomy require 
blood transfusion19.   
The main source of hemorrhage in these patients is parenchymal 
vessels. On table, the access sheath acts as a tamponade. If there is 
bleeding postoperatively the nephrostomy tube can be inserted and kept 
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closed. The incision can be compressed as well and the clots removed 
from the collecting system. If the above measures do not control 
hemorrhage, we can go for selective angioembolisation29. 
 Delayed hemorrhage is seen in around 1% of the patients and it is 
due to arteriovenous fistulas or pseudoaneurysms.  
Angiography followed by selective embolization of the vessels is 
the treatment of choice for these complications. 
Recent advancement in the treatment is the placement of 
endovascular stents inside the bleeding vessel followed by ultrasound 
guided injection of thrombin or tissue adhesive30. 
Injury of the collecting system like pelvic perforation might occur 
which is identified by sudden collapse of the renal pelvis. This results in 
massive extravasation of fluid. If the perforation occurs the procedure 
should be stopped followed by placement of both nephrostomy tube and 
ureteral stent31. 
Injury to the abdominal viscera like colon, duodenum and jejunum 
can occur in some patients. Patients with extraperitoneal colonic injury 
can be managed conservatively by placing separate drainage for colon 
and kidney32. Intraperitoneal injury has to be repaired. Liver and splenic 
injuries rarely occur. 
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In supracostal access, pleural and lung injuries most likely occur. A 
costal drainage is placed in such types of injuries33. 
In some patients where normal saline is used for irrigation, it might 
get extravasated at times resulting in metabolic and electrolyte imbalance. 
Venous gas embolism if occurs proves to be fatal. 
Fever occurs in 15% – 30% of the patients postoperatively. Despite 
the use of prophylactic antibiotics systemic inflammatory response also 
occurs in a few patients.1%-2% patients develop frank sepsis ultimately. 
Various studies conducted so far suggest that preoperative 
treatment of only those patients with positive urine culture is not enough 
as postoperative sepsis has also developed in those patients with sterile 
preoperative urine cultures.  
Hence it is important to treat the fever patients with full course of 
antibiotics to prevent the development of sepsis following PCNL34.  
TUBELESS PERCUTANEOUS NEPHROLITHOTOMY 
Formerly the opinion was that placement of nephrostomy tubes has 
many advantages like maintenance of hemostasis along the tract and 
prevention of extravasation of urine while adequately draining the 
kidney35. Nevertheless the basic purpose of placing a nephrostomy tube is 
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only adequate drainage of the kidney the concept of tubeless PCNL was 
proposed.  
The tubeless procedure is nothing but placement of a ureteral stent 
or a catheter without a nephrostomy tube to provide adequate drainage of 
the kidney after PCNL.   
The concept of tubeless procedure was considered even in the early 
period of evolution of PCNL, the proof being a study conducted by 
Wickham in 198436 on 100 patients in whom neither external drainage 
nor internal drainage tubes were placed and the results were published. 
The results were encouraging and the patients who underwent this 
procedure were discharged within 24 hrs and the conclusion was that the 
tubeless PCNL was harmless and effective with a relatively shorter 
admission period.  
But later Winfield and associates35 provided a report about two 
patients who underwent nephrostomy tube removal prematurely 
following a simple upper urinary tract calculi extraction. These patients 
later developed complications like life threatening hemorrhage requiring 
blood transfusion, significant amount of urinary extravasation and 
therefore they had to undergo internal stenting and consecutively had a 
prolonged hospital stay. And hence the recommendation was that for the 
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initial 24 to 48 hrs following PCNL drainage with a nephrostomy tube 
must be provided. This turned out to be the standard procedure in the 
following years globally. 
Again in 1997 Bellman et al37opposed the practice of routine 
insertion of a nephrostomy tube following PCNL. They conducted a 
study in which 50 patients were in the study group and 50 patients were 
in the control group. The study group underwent tubeless PCNL 
procedure in which only ureteral stents were placed inside and no 
nephrostomy tubes were kept whereas the control group underwent the 
standard PCNL procedure with the placement of a nephrostomy tube. 
The length of hospital stay, requirements of analgesics, time taken 
to come back to normal and the total cost were the parameters compared 
between the two groups. 
 The conclusion was that the study group had a shorter hospital 
stay with less analgesic requirements and lesser hospital expenses and 
they returned to their routine life quicker compared to the study group. 
Candela and colleagues38 studied the cost of a standard PCNL 
versus a tubeless procedure and published that the cost of standard 
procedure was high compared to that of a tubeless procedure.   
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Numerous studies conducted so far had shown that tubeless PCNL 
is comparatively good and harmless and also morbidity is lesser if done in 
selected patients (39-42). 
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MATERIALS & METHODS 
SUBJECT SELECTION:    
Cases include patients with renal calculus disease who undergo 
PCNL for the same in the Dept. of Urology. It is a prospective study done 
between April 2013 to March 2014. 
100 cases of stone disease with stone size more than 2 cm who 
undergo PCNL in the Dept. of Urology, Madras Medical College. 
Patients are divided into two groups (Group A& Group B) 
1. Group A - 50 cases of tubeless PCNL 
2. Group B - 50 cases of standard PCNL 
INCLUSION CRITERIA:     
1. Stone size more than 2 cm who underwent PCNL as primary 
procedure 
2. Single puncture tract 
3. Procedure lasting less than 2 hrs  
4. Less than three stones with a diameter <25 mm 
5. Complete extraction of all stones 
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6. No significant bleeding at the end of the procedure 
. 
EXCLUSION CRITERIA:    
1. Residual calculi 
2. Significant bleeding at the end of procedure 
3. Multiple puncture tract 
METHOD OF STUDY 
INVESTIGATIONS 
Patient were evaluated with physical examination, urine analysis, 
urine culture and sensitivity , complete blood count , renal function test , 
X-ray KUB, and Plain and contrast enhanced computerized tomography / 
IVP 
Group A underwent tubeless PCNL and Group B underwent 
standard PCNL after obtaining anesthetic fitness for the procedure. 
All patients were administered 1 gm of ceftriaxone and 500 mg of 
amikacin as standard antibiotic prophylaxis for a period of three days 
including one preoperative dose. Patients with preoperative serum 
creatinine greater than 1.4 were not administered amikacin. 
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All patients underwent PCNL under general anesthesia. Patients 
were placed in lithotomy position and a 5 Fr ureteric catheter was 
introduced. Contrast was used to identify the collecting system and to 
select the calyx for puncture. 
After prone positioning with adequate padding posterior calyceal 
puncture was done under fluoroscopic guidance. Level of puncture was 
decided as per location of stone to ensure complete clearance. 
Puncture was done using 18 G three part needle and guide wire 
was placed within the system. Guide rod was introduced and serial 
coaxial dilatation of tract done with Alkens metal dilator. Amplatz sheath 
was placed. Using 26 Fr KarlStorz nephroscope and KarlStorz pneumatic 
lithotripter stone fragmentation was done. 
After fragments were evacuated antegrade 5 Fr ureteric stent was 
placed in group A and skin incision sutured and compression bandage 
applied. A 20 Fr nephrostomy tube along with 5 Fr ureteric stent was 
placed in patients coming under group B. 
Preop parameters like stone size, stone disease in the opposite 
kidney and ureter, preop creatinine and associated comorbidities were 
recorded. 
Intraoperative parameters like operative time, access tract and the 
need for blood transfusion were recorded. 
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  tube  
 
  
 
 
 
 
 
 
 
Post of Xray KUB – Standard PCNL 
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Patients were followed up in post op period with drop in Hb, need 
for blood transfusion, need for analgesia, hospital stay, complications and 
need for ancillary procedure.  
Post procedure check X-ray KUB was taken before removing the 
nephrostomy tube in the first postoperative day in the standard PCNL 
group. Calculi size more than 4 mm consider residual calculi.In both 
group A&B ureteric stent was removed after 14 days. 
 
DATA COLLECTION METHODS 
Stone size, preop creatinine, operative rate,stone clearance 
rate,Length of hospital stay, analgesic requirements and postoperative 
complications such as bleeding, infection or ureteral obstruction, Hospital 
readmission rates were recorded and compared. 
STATISTICAL ANALYSIS OF THE STUDY 
For discrete data proportion are computed and the mean and 
standard deviation are computed for the continuous data. The chi square 
test was applied to compare the proportions between the groups.  All 
analyses were two tailed and p <0.05 was considered significant. 
Independent sample T test was used to compare the difference between 
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two groups. Statistical package for social sciences (SPSS) version 17.0 
was used for data analysis.  
Concept of P value 
 If the P value is  0.000 to  0.010, then denoted by **, it implies 
Significant at 1 level (Highly Significant ) 
 If the P value is 0.011 to 0.050, then denoted by *, it implies 
Significant at 5 level (Significant ) 
 If the P value is 0.051 to 1.000, then not given a star, it implies Not 
Significant at 5 level(Not Significant) 
Note: If the P value is .000 then write it as <0.001** 
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OBSERVATION AND RESULTS 
TABLE-1: AGE DISTRIBUTION-DESCRIPTIVE STATISTICS 
 
 
 N Minimum Maximum Mean Std. Deviation 
Age in years 50 13 65 37.78 12.671 
 
In group A, the lowest age was 13 and the highest age was 65 (table-1). 
 
TABLE-2: COMORBIDITY - FREQUENCY TABLE 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Nil 36 72.0 72.0 72.0 
 Hypertension 5 10.0 10.0 82.0 
 DM 7 14.0 14.0 96.0 
 Both 2 4.0 4.0 100.0 
 Total 50 100.0 100.0  
 
In group A, 10% of patients had Hypertension, 14% had diabetes 
mellitus, and 4% had both diabetes mellitus and Hypertension (table-2). 
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TABLE-3: PREOP CREATININE-DESCRIPTIVE STATISTICS 
 N Minimum Maximum Mean Std. Deviation 
Pre op 
creatinine 50 .6 2.0 .908 .3200 
 
In group A, the lowest creatinine was 0.6 and the highest creatinine 
was 2.0. Mean was 0.908 (table-3). 
TABLE-4: ASSOCIATED STONE DISEASE – FREQUENCY 
TABLE 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 
Ureteric 
calculi 3 6.0 33.3 33.3 
Bilateral 3(6 renal units) 6.0 33.3 33.3 
Total 6 12.0 100.0  
Missing System 41 82.0   
Total 50 100.0   
 
In group A, 6% of patients had ureteric calculi and 6% had bilateral 
stone disease (table-4). 
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TABLE-5: PUNCTURE SITE - FREQUENCY TABLE 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 
Inferior 
calyx 36 72.0 72.0 72.0 
Middle 
calyx 9 18.0 18.0 90.0 
Superior 
calyx 5 10.0 10.0 100.0 
Total 50 100.0 100.0  
 
In group A, 72% underwent inferior calyceal puncture, 18% 
underwent middle calyceal puncture and 10% underwent superior 
calyceal puncture  (table-5). 
 
 
 
  
37 
 
GENDER OUTCOME 
TABLE-6: GENDER DISTRIBUTION CROSSTABLE 
  
Group 
Total 
 
Group A Group B p-value 
Sex 
Male 
Count 32 32 64 
1.000 % within 
Sex 50.0% 
50.0% 100.0% 
% within 
Group 64.0% 
64.0% 64.0% 
Female 
Count 18 18 36 1.000 
% within 
Sex 50.0% 
50.0% 100.0% 
% within 
Group 36.0% 
36.0% 36.0% 
Total 
Count 50 50 100  
% within 
Sex 50.0% 
50.0% 100.0%  
% within 
Group 100.0% 
100.0% 100.0%  
 
(a)  Computed only for a 2x2 table 
(b)  0 cells (.0%) have expected count less than 5. The minimum expected 
count is 18.00. 
In this study of 100 patients 64(64%) of them were males and 36 
(36%) were females. 
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 In group A, 32(64%) patients were males and 18(36%) patients 
were females. In group B, 32 (64%) patients were males and 18(36%) 
patients were females (table-6). 
On statistical analysis using Chi-square test, it was found that the 
gender distribution between those of group A and group B was not 
statistically significant. (p= 1.000), (table- 6). 
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TABLE-7: LATERALITY DISTRIBUTION CROSSTABLE 
  
Group 
Total 
Group A Group B 
Side 
Left 
Count 26 21 47 
% within 
Side 55.3% 
44.7% 100.0% 
% within 
Group 52.0% 
42.0% 47.0% 
Right 
Count 24 29 53 
% within 
Side 45.3% 
54.7% 100.0% 
% within 
Group 48.0% 
58.0% 53.0% 
Total 
Count 50 50 100 
% within 
Side 50.0% 
50.0% 100.0% 
% within 
Group 100.0% 
100.0% 100.0% 
 
In this study, 47(47%) patients had stone on the left side and 
53(53%) patients had stone on the right side. 
In group A, 26(52%) patients had stone on the left side and 
24(48%) patient had stone on the right side. In group B, 21(42%) patients 
had stone on the left side and 29(58%) patients had stone on the right 
side.(table-7)  
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TAB-8: LATERALITY DISTRIBUTION ANALYSIS CHI-
SQUARE TESTS 
 Value df Asymp. Sig. (2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-
Square 
1.004 
(b) 
1 .316   
Continuity 
Correction(a) 
.642 1 .423   
Likelihood Ratio 1.005 1 .316   
Fisher's Exact Test    .423 .212 
Linear-by-Linear 
Association 
.994 1 .319   
No of Valid Cases 100     
 
(a)  Computed only for a 2x2 table 
(b)  0 cells (.0%) have expected count less than 5. The minimum expected 
count is 23.50. 
On statistical analysis using Chi-square test, it was found that the 
laterality between those of group A and group B was not statistically 
significant (p= 0.423), (table- 8). 
  
FIGURE–02: LATERALITY DISTRIBUTION 
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TABLE-9: COMORBIDITY DISTRIBUTION CROSSTABLE 
  Group Total 
  Group A 
Group 
B  
Comorbidity Nil Count 36 35 71 
  % within Comorbidity 50.7% 49.3% 100.0% 
  % within Group 72.0% 70.0% 71.0% 
 Hyperten sion Count 5 4 9 
  % within Comorbidity 55.6% 44.4% 100.0% 
  % within Group 10.0% 8.0% 9.0% 
 Diabetes Mellitus Count 7 9 16 
  % within Comorbidity 43.8% 56.3% 100.0% 
  % within Group 14.0% 18.0% 16.0% 
 Both Count 2 2 4 
  % within Comorbidity 50.0% 50.0% 100.0% 
  % within Group 4.0% 4.0% 4.0% 
Total Count 50 50 100 
 % within Comorbidity 50.0% 50.0% 100.0% 
 % within Group 100.0% 100.0% 100.0% 
 
In this study 16(16%) patients had diabetes mellitus, 9(9%) had 
hypertension and 4(4%) patients had both diseases. 
Among the group A patients, 7(14%) patients had diabetes 
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mellitus, 5(5%) had hypertension and 2(4%) had both. Among the group 
B patients, 9(18%) patients had diabetes mellitus, 4(8%) had 
hypertension and 2(4%) had both. (table- 9). 
 
TABLE-10: COMORBIDITY DISTRIBUTION ANALYSIS  
CHI-SQUARE TESTS 
 Value Df Asymp. Sig. (2-sided) 
Pearson Chi-Square .375(a) 3 .945 
Likelihood Ratio .376 3 .945 
Linear-by-Linear 
Association .110 1 .740 
No of Valid Cases 100   
 
(a) 4 cells (50.0%) have expected count less than 5. The minimum 
expected count is 2.00. 
On statistical analysis using Chi-square test, it was found that the 
comorbidity between those of group A and group B was not statistically 
significant (p= 0.945) (table-10). 
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TABLE-11: PUNCTURE SITE DISTRIBUTION CROSSTABLE 
  
Group 
Total Group 
A 
Group 
B 
Puncture site 
Inferior 
calyx 
Count 36 38 74 
% within 
Puncture site 48.6% 51.4% 100.0% 
% within 
Group 72.0% 76.0% 74.0% 
Middle 
calyx 
Count 9 8 17 
% within 
Puncture site 52.9% 47.1% 100.0% 
% within 
Group 18.0% 16.0% 17.0% 
Superior 
calyx 
Count 5 4 9 
% within 
Puncture site 55.6% 44.4% 100.0% 
% within 
Group 10.0% 8.0% 9.0% 
Total 
Count 50 50 100 
% within 
Puncture site 50.0% 50.0% 100.0% 
% within 
Group 100.0% 100.0% 100.0% 
 
In this study, 74 (74%) patients underwent lower calyceal puncture, 
17 (17%) patients underwent middle calyceal puncture and 9(9%) 
underwent upper calyceal puncture. 
In group A, 36(72%) patients underwent lower calyceal puncture, 
9(18%) patients underwent middle calyceal puncture and 5(10%) 
underwent upper calyceal puncture. In group B, 38(76%) patients 
underwent lower calyceal puncture, 8(16%) patients underwent middle 
calyceal puncture and 4(8%) underwent upper calyceal puncture (table-
11). 
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TABLE-12: PUNCTURE SITE DISTRIBUTION ANALYSIS  
CHI-SQUARE TESTS 
 Value Df Asymp. Sig. (2-sided) 
Pearson Chi-Square .224(a) 2 .894 
Likelihood Ratio .224 2 .894 
Linear-by-Linear 
Association .219 1 .640 
No of Valid Cases 100   
 
(a) 2 cells (33.3%) have expected count less than 5. The minimum 
expected count is 4.50. 
On statistical analysis using Chi-square test, it was found that the 
puncture site between those of group A and group B was not statistically 
significant (p= 0.894) (table- 12). 
 
 
 
  
FIGURE-04: PUNCTURE SITE DISTRIBUTION 
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TABLE-13: COMPLICATIONS DISTRIBUTION CROSSTABLE 
  
Group 
Total Group 
A 
Group 
B 
Complica
tions 
No complica 
tions 
Count 44 43 87 
% within 
Complications 50.6% 49.4% 100.0% 
% within Group 88.0% 86.0% 87.0% 
Hematuria 
Count 1 2 3 
% within 
Complications 33.3% 66.7% 100.0% 
% within Group 2.0% 4.0% 3.0% 
Urosepsis 
Count 5 5 10 
% within 
Complications 50.0% 50.0% 100.0% 
% within Group 10.0% 10.0% 10.0% 
Total 
Count 50 50 100 
% within 
Complications 50.0% 50.0% 100.0% 
% within Group 100.0% 100.0% 100.0% 
 
In this study, 3(3%) patients developed hematuria and 10(10%) 
patients developed urosepsis. 
Among those in group A, 1(2%) patient had hematuria and 5(10%) 
patients had urosepsis. In group B, 2(4%) patients had hematuria and 
5(10%) patients had urosepsis (table-13). All these patients were 
managed conservatively. One patient in group A had urosepsis with PCS 
dilatation and underwent PCN (table-13).  
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TABLE- 14: COMPLICATIONS DISTRIBUTION ANALYSIS 
 CHI-SQUARE TESTS 
 Value Df Asymp. Sig. (2-sided) 
Pearson Chi-Square .345(a) 2 .842 
Likelihood Ratio .351 2 .839 
Linear-by-Linear 
Association .026 1 .871 
No of Valid Cases 100   
 
(a) 2 cells (33.3%) have expected count less than 5. The minimum 
expected count is 1.50. 
On statistical analysis using Chi-square test, it was found that the 
complication rate between those of group A and group B was not 
statistically significant (p= 0.842)(table-14). 
 
 
 
 
  
FIGURE-05: COMPLICATIONS 
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TABLE- 15: COMPLICATIONS 
Comorbidity   
Group Total 
p-
valu
e 
  
Grou
p A 
Grou
p B  
 
Nil Complica
tion 
No 
complicati
on 
Count 
33 35 68 
 
0.21
8 
   % within 
Complicati
on 
48.5% 51.5% 100.0% 
   % within 
Group 91.7% 
100.0
% 95.8% 
  Bleeding Count 1 0 1 
   % within 
Complicati
on 
100.0
% .0% 
100.0
% 
   % within 
Group 2.8% .0% 1.4% 
  Uro sepsis Count 2 0 2 
   % within 
Complicati
on 
100.0
% .0% 
100.0
% 
   % within 
Group 5.6% .0% 2.8% 
 Total Count 36 35 71 
 % within 
Complicati
on 
50.7% 49.3% 100.0% 
 % within 
Group 
100.0
% 
100.0
% 
100.0
% 
Hypertension Complica
tion 
No 
complicati
on 
Count 
4 2 6 
 
0.45
5 
   % within 
Complicati
on 
66.7% 33.3% 100.0% 
   % within 
Group 80.0% 50.0% 66.7% 
  Bleeding Count 0 1 1 
   % within 
Complicati
on 
.0% 100.0% 
100.0
% 
   % within 
Group .0% 25.0% 11.1% 
 
  Uro sepsis Count 1 1 2 
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   % within 
Complicati
on 
50.0% 50.0% 100.0% 
   % within 
Group 20.0% 25.0% 22.2% 
 Total Count 5 4 9 
 % within 
Complicati
on 
55.6% 44.4% 100.0% 
 
 % within 
Group 
100.0
% 
100.0
% 
100.0
% 
 
DM Complica
tion 
No 
complicati
on 
Count 
6 6 12 
 
0.38
3 
   % within 
Complicati
on 
50.0% 50.0% 100.0% 
   % within 
Group 85.7% 66.7% 75.0% 
  Uro sepsis Count 1 3 4 
   % within 
Complicati
on 
25.0% 75.0% 100.0% 
   % within 
Group 14.3% 33.3% 25.0% 
 Total Count 7 9 16 
 % within 
Complicati
on 
43.8% 56.3% 100.0% 
 
 % within 
Group 
100.0
% 
100.0
% 
100.0
% 
 
Both Complica
tion 
No 
complicati
on 
Count 
1 0 1 
 
0.36
8 
   % within 
Complicati
on 
100.0
% .0% 
100.0
% 
   % within 
Group 50.0% .0% 25.0% 
  Bleeding Count 0 1 1 
   % within 
Complicati
on 
.0% 100.0% 
100.0
% 
   % within 
Group .0% 50.0% 25.0% 
  Uro sepsis Count 1 1 2 
   % within 
Complicati 50.0% 50.0% 
100.0
% 
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on 
   % within 
Group 50.0% 50.0% 50.0% 
 Total Count 2 2 4 
 % within 
Complicati
on 
50.0% 50.0% 100.0% 
 
 % within 
Group 
100.0
% 
100.0
% 
100.0
% 
 
 
In this study there is no difference between complication rate in patients 
with comorbidity between two groups.(tab-15) 
 
 
  
50 
 
TABLE-16: STONE CLEARANCE DISTRIBUTION 
CROSSTABLE 
  
Group 
Total 
Group 
A 
Group 
B 
Stone 
clearance 
Complete Count 48 47 95 
% within 
Stone 
clearance 
50.5% 49.5% 100.0% 
% within 
Group 96.0% 94.0% 95.0% 
Incomplete Count 2 3 5 
% within 
Stone 
clearance 
40.0% 60.0% 100.0% 
% within 
Group 4.0% 6.0% 5.0% 
Total Count 50 50 100 
% within 
Stone 
clearance 
50.0% 50.0% 100.0% 
% within 
Group 100.0% 100.0% 100.0% 
 
In this study, 94(94%) patients had complete stone clearance. 
Among group A patients, 48(96%) had complete stone clearance. 
Among group B patients, 46(94%) had complete stone clearance 
(table-16). 
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TAB-17: STONE CLEARANCE RATE ANALYSIS CHI-SQUARE 
TESTS 
 Value df 
Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Pearson Chi-
Square .211(b) 1 .646   
Continuity 
Correction(a) .000 1 1.000   
Likelihood 
Ratio .212 1 .645   
Fisher's Exact 
Test    1.000 .500 
Linear-by-
Linear 
Association 
.208 1 .648   
N of Valid 
Cases 100     
 
(a) Computed only for a 2x2 table 
(b) 2 cells (50.0%) have expected count less than 5. The minimum 
expected count is 3.00. 
On statistical analysis using Chi-square test it was found that the 
stone clearance between those of group A and group B was not 
statistically significant (p= 0.845)(table- 17). 
  
FIGURE-6: STONE CLEARANCE RATE 
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TABLE-18: ANCILLARY PROCEDURE DISTRIBUTION 
CROSSTABLE 
  Group Total Group A Group B 
Ancillary 
procedure 
Nil 
Count 44 43 87 
% within 
Ancillary 
procedure 
50.6% 49.4% 100.0% 
% within 
Group 88.0% 86.0% 87.0% 
L URS 
Count 1 2 3 
% within 
Ancillary 
procedure 
33.3% 66.7% 100.0% 
% within 
Group 2.0% 4.0% 3.0% 
R URS 
Count 2 3 5 
% within 
Ancillary 
procedure 
40.0% 60.0% 100.0% 
% within 
Group 4.0% 6.0% 5.0% 
ESWL 
Count 2 2 4 
% within 
Ancillary 
procedure 
50.0% 50.0% 100.0% 
% within 
Group 4.0% 4.0% 4.0% 
PCN 
Count 1 0 1 
% within 
Ancillary 
procedure 
100.0% .0% 100.0% 
% within 
Group 2.0% .0% 1.0% 
Total 
Count 50 50 100 
% within 
Ancillary 
procedure 
50.0% 50.0% 100.0% 
% within 
Group 100.0% 100.0% 100.0% 
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In this study, 3(3%) patients required LT URS for left ureteric 
calculus, 5(5%) patients required RT URS, 4 (4%) patient needed ESWL 
and 1(1%) patient underwent PCN. 
In group A, 1(2%) patient required LT URS for left ureteric 
calculus, 2(4%) patients required RT URS, 2(4%) patients needed ESWL 
and 1(2%) patient underwent PCN. In group B, 2(4%) patients required 
LT URS for left ureteric calculus, 3(6%) patients required RT URS, 
2(4%) patient needed ESWL and no patient underwent PCN (table-18). 
TABLE-19: ANCILLARY PROCEDURE DISTRIBUTION 
ANALYSIS CHI-SQUARE TESTS 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 1.545(a) 4 .819 
Likelihood Ratio 1.939 4 .747 
Linear-by-Linear 
Association .015 1 .903 
No of Valid Cases 100   
 
(a) 8 cells (80.0%) have expected count less than 5. The minimum 
expected count is .50. 
On statistical analysis using Chi-square test, it was found that the 
number of ancillary procedures done between those of group A and group 
B was not statistically significant (table-19).
  
FIGURE-7: ANCILLARY PROCEDURE 
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TABLE-20: T-TEST-GROUP STATISTICS 
 Group N Mean Std. Deviation 
Std. 
Error 
Mean 
p-
value 
Age in 
years 
Group A 50 37.78 12.671 1.792 
0.409 
Group B 50 39.86 12.400 1.754 
Stone size 
Group A 50 2.998 .4649 .0657 
0.333 
Group B 50 3.088 .4605 .0651 
Operation 
time 
Group A 50 54.94 4.766 .674 
0.693 
Group B 50 54.62 3.162 .447 
Drop in HB 
Group A 50 .744 .2589 .0366 
0.777 
Group B 50 .760 .3030 .0429 
No. of 
blood 
transfusion 
Group A 50 .10 .303 .043 
0.448 
Group B 50 .16 .468 .066 
Analgesic 
requirement 
Group A 50 121.00 30.456 4.307 
0.000 
Group B 50 170.00 31.944 4.518 
Hospital 
stay 
Group A 50 3.32 .768 .109 
0.000 
Group B 50 4.16 .422 .060 
Pre op 
creatinine 
Group A 50 .908 .3200 .0453 
0.847 
Group B 50 .920 .3003 .0425 
 
In this study, average age in group A was 37.78 yrs and group B’s 
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average age was 39.89 yrs.  
Group A’s average stone size was 2.998 cm and group B’s average 
stone size was 3.088 cm. 
Group A’s average operation time was 54.94 min and group B’s 
average operation time was 54.62 min. 
Group A’s average drop in HB was 0.744 g% and group B’s 
average drop in HB was 0.760 g%. 
In group A, 10% of patients required blood transfusion and in 
group B, 16% of patients needed blood transfusion.  
In group A, the average amount of analgesic requirement was 
121mg of tramadol and in group B, the average amount of analgesic 
requirement was 170mg of tramadol. 
Average no. of days of hospital stay for group A was 3.32 days and 
for group B, the average no. of days of hospital stay was 4.16 days 
In group A, the average preop creatinine value was 0.908 mg/dl 
and in group B, the average preop creatinine value was 0.920 mg/dl 
(table-20). 
On statistical analysis,  
1. Age of the patient between those of group A and group B was not 
statistically significant (P-0.409) (table-20). 
2. Stone size between those of group A and group B was not 
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statistically significant (P-0.333) (table-20). 
3. Operation time between those of group A and group B was not 
statistically significant (P-0.693) (table-20). 
4. Drop in HB between those of group A and group B was not 
statistically significant (P-0.777) (table-20). 
5. Blood transfusion rate between those of group A and group B was not 
statistically significant (P<0.001) (table-20). 
6. Analgesic requirement between those of group A and group B was 
not statistically significant (P<0.001) (table-20). 
7. Preop creatinine between those of group A and group B was not 
statistically significant (P-0.847) (table-20). 
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DISCUSSION 
Renal stone disease is one of the most common urological 
problems. Medical management may not be feasible in all circumstances. 
Surgical management is more effective in treatment of stone disease. 
Furthermore medical management is more helpful in preventing 
recurrences following surgical removal rather than as primary therapy. 
Surgical management as previously explained comprises both open 
and endourological procedures. In the contemporary age renal calculus 
surgery is always done through minimal access procedures.Over a period, 
PCNL has developed to be a safer and relatively less morbid procedure 
when compared to an open stone surgery. Due to its lesser cost, shorter 
operative time, minimal requirement for blood transfusion and analgesics 
and ability of the patients to regain their routine daily life activities 
sooner make PCNL the preferred procedure at recent times. 
The procedure when attempted initially was time consuming, 
tedious for both patient and treating surgeon and with considerable 
morbidity and some mortality. 
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Because of technical improvements in imaging and optics and with 
better understanding of the pathology behind the significant morbidity, 
the procedure has been standardized. 
To begin with, gaining an access was believed to be a crucial step 
in the success of the procedure. With an excellent preoperative imaging 
provided by the reconstructed computerised tomography nowadays, 
localization and delineation of the extent of calculi is far better. Excellent 
demarcation of pelvicalyceal anatomy has facilitated   in gaining an easier 
access to the pelvicalyceal system.  Furthermore technical advancements 
like fluoroscopic and ultrasonographic guided attempts to gain an access 
helped out in effectively creating a tract into the pelvicalyceal system. As 
already mentioned there are antegrade and retrograde techniques of 
access into the pelvicalyceal system but still the most preferred route is 
the antegrade access. 
Surgical skills in PCNL improved a lot during the years and the 
procedure has become more perfect, meaning that the tract made is just 
sufficient for the procedure to be done and unnecessary tissue handling is 
avoided. This is an important step in the increase in success rates of the 
procedure in recent years. 
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Dilatation of the tract is accomplished by various types of dilators 
like coaxial Alken dilators, Amplatz semirigid dilators and balloon 
dilators. All these dilators have aided in establishing a successful tract. 
Improvements in optics and miniaturization of endo instruments 
have also lessened the morbidity rates and thus increased the success rate. 
With the introduction of flexible instruments, we have a better access to 
all parts of the collecting system without a necessity for additional tracts. 
Improvements in intracorporeal lithotripters have also increased the 
success rate of percutaneous nephrolithotomy. Smaller sized lithotripter 
probes and effective retrieval of stone fragments have enhanced the 
outcome of the procedure. 
Despite the advancements and subsequent perfections, a few 
morbidities continue to affect the patients. Nephrostomy tube kept after 
the procedure adds to the patient’s discomfort. 
In our study we compared tubeless PCNL vs standard PCNL in 
patients with stone disease. 
Tubeless PCNL was performed with success in patients of age 13 
yrs to 65yrs. 
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Tubeless PCNL was done even in patients with elevated renal 
parameters as 5(10%) patients in group A had elevated renal parameters. 
The highest creatinine value in group A is 2mg/dl. 
Tubeless PCNL was safely done even in patients with DM, HTN as 
5(10%) patients had HTN and 7(14%) patients had DM and 2(4%) had 
both in tubeless PCNL group. 
Tubeless PCNL was done in patients with stone disease 
irrespective of tract location (upper, middle or lower). 
In tubeless PCNL group 3(6%) of the patients had B/L stone 
disease and underwent B/L tubeless PCNL in two sittings. 
3(6%) patients had associated ureteric calculi and underwent URS 
and PCNL in the same sitting. 
Operative time in both the groups was similar.(GROUP A 54.92 
Minvs GROUP B 54.62 Min). 
The postoperative drop in HB and blood transfusion rate was 
similar in both groups under study. 
Presence of residual calculi was similar in both the groups and 
these residual calculi were treated with ESWL. 
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The need for post op analgesia was less with tubeless PCNL 
group.The Group A patients needed 121 mg OF Tramadol whereas Group 
B needed 170mg. This is statistically significant with a p value of<0.001. 
A study conducted by both Madhu S. Agrawal etal & 
B.Lojanapiwat et al showed similar results. 
Post op complications were similar in both groups. Postop 
complications in both the groups were managed conservatively .But one 
patient from group A developed urosepsis with PCS dilatation. This 
patient underwent PCN. 
Length of Postoperative hospital stay was longer in standard PCNL 
group (4.16 days) compared to the tubeless PCNL group(3.32 days).This 
is statistically significant with a p value of <0.001. 
Studies conducted by Madhu S. Agrawalet al,B.Lojanapiwat et 
al,Hemendra Shah et al also showed similar results. 
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CONCLUSION 
Tubeless PCNL is a relative safe procedure even in patients with 
elevated renal parameters and in those with associated comorbid 
conditions. 
Tubeless PCNL is safe in any tract location (upper, middle, lower). 
. Tubeless PCNL can be safely done even in patients with bilateral 
disease.  
Tubeless PCNL requires less analgesics and less hospital stay. 
Both standard and tubeless PCNL have similar post op 
complication rate. 
Tubeless PCNL is a very safe and  very effective procedure if done 
in selected group of patients. 
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APPENDIX 1 
 
                                       INFORMED CONSENT FORM  
Title of the study:  A COMPARATIVE STUDY OF STANDARD  
VERSUS  TUBELESS PERCUTANEOUS  NEPHROLITHOTOMY 
Name of the Participant:   
Name of the Principal Investigator:   Dr. NAVEEN.S  
Name of the Institution:   
Madras Medical College and Rajiv Gandhi Government General 
Hospital,  
Chennai- 3  
Name and address of the sponsor / agency: Nil  
Documentation of the informed consent  
I have read the information in this form (or it has been read to me). I  
was free to ask any questions and they have been answered. I am over 18  
years of age and, exercising my free power of choice, hereby give my  
consent to be included as a participant in ―A COMPARATIVE 
STUDY OF STANDARD VERSUS TUBELESS PERCUTANEOUS 
NEPHROLITHOTOMY 
1.  I have read and understood this consent form and the information 
provided to me.  
2.  I have had the consent document explained to me.  
3.  I have been explained about the nature of the study.  
 4.  I have been explained about my rights and responsibilities by the 
investigator.  
  
5.  I have been informed the investigator of all the treatments I am taking 
or have taken in the past ____ months including any native (alternative) 
treatment.  
6.  I have been advised about the risks associated with my participation in 
this study.  
7.  I agree to cooperate with the investigator and I will inform him/her 
immediately if I suffer unusual symptoms.   
8.  I have not participated in any research study within the past 
______month(s). 
9. I am aware of the fact that I can opt out of the study at any time 
without having to give any reason and this will not affect my future 
treatment in this hospital.   
10.  I am also aware that the investigator may terminate my participation 
in the study at any time, for any reason, without my consent.   
11.  I hereby give permission to the investigators to release the 
information obtained from me as result of participation in this study to the 
sponsors, regulatory authorities, government agencies, and IEC. I 
understand that they are publicly presented.  
12.  I have understood that my identity will be kept confidential if my 
data are publicly presented.  
 13.  I have had my questions answered to my satisfaction.  
14.  I have decided to be in the research study. I am aware that if I have 
any question during this study, I should contact the investigator. By 
signing this consent form I attest that the information given in this 
  
document has been clearly explained to me and understood by me, I will 
be given a copy of this consent document. For adult participants:  
Name and signature / thumb impression of the participant  
Name _________________________ Signature_________________  
Date________________  
Name and Signature of impartial witness(for illiterate patients):  
Name_________________________ Signature_________________  
Date________________  
Address and contact number of the impartial witness:  
Name and Signature of the investigator or his representative obtaining  
consent:  
Name_________________________ Signature_________________  
Date________________  
For Children being enrolled in research:  
Whether child‘s assent was asked: Yes / No (Tick one)  
[If the answer to be above question is yes, write the following phrase:  
You agree with the manner in which assent was asked for from your child  
and given by your child. You agree to have your child take part in this  
study].  
[If answer to be above question No, give reason (s)  
_____________________________  
  
Although your child did not or could not give his or her assent, you agree  
to your child‘s participation in this study.   
Name and Signature of / thumb impression of the participant‘s parent(s)  
(or legal representative)  
Name_________________________ Signature_________________  
Date________________  
Name_________________________ Signature_________________  
Date________________  
Name and Signature of impartial witness (required for parents of  
participant child illiterate):  
Name_________________________ Signature_________________  
Date________________  
Address and contact number of the impartial witness:  
__________________________________  
 
Name and Signature of the investigator or his representative obtaining  
consent : 
Name_________________________ Signature_________________ 
 
Date-------------- 
  
 
  
 
 
 
  
                                            APPENDIX 2 
                                             PROFORMA 
 
Name:                                                                          Age:                   Sex: 
 
Ip No: 
Address: 
 
Chief complaints: 
Comorbidity 
DM 
HTN 
ASTHMA 
IHD 
Past medical/surgical history 
Examination 
  
PR:                            BP:                                  
R/S:                                    CVS: 
P/A: 
EG: 
 CBC: 
RFT: 
X ray KUB: 
USG KUB: 
CECT KUB/IVP:                                                      Stone Size: 
Intra op 
Operation time:                            Puncture site:                    
Nephrostomy: Yes/No 
Drop in HB:                                  No of blood transfusion: 
Anelgesia:                                                Stone clearance: 
Complication:                                          Ancillary procedure: 
No of days hospital stay: 
  
APPENDIX 3 
 
  
APPENDIX 4 
MASTER CHART 
SERI
AL 
NO 
NAME AG
E 
(yrs
) 
SE
X 
GRO
UP 
SIDE STO
NE 
SIZE 
COMORBID
ITY 
PUNCTU
RE SITE  
OPERATI
ON 
TIME(mi
n) 
DR
OP 
IN 
HB 
(g%) 
NO. OF 
BLOOD 
TRANSFUS
ION 
ANALGESI
C 
REQUIREM
ENT 
(Tramadol) 
HOSPIT
AL 
STAY 
(days) 
COMPLICATI
ONS 
STONE 
CLEARA
NCE 
PRE OP 
CREATIN
INE 
(mg/dl) 
ANCILLA
RY 
PROCED
URE 
1 Karunakaran 28y M A R 2.5 NO Inferior 
calyx 
40 0.9 NIL 100mg 3 No Complete 0.8 NO 
2 Hemalatha 13y F A L-R U 3 NO Inferior 
calyx 
53 1 1 100mg 3 No Complete 0.7 R-URS 
3 Thirumalai 
samy 
46y M A L 2.9 NO Inferior 
calyx 
54 0.6 NIL 100mg 3 No Complete 0.6 NO 
4 Madhu 48y F A R 3.3 DM Inferior 
calyx 
43 0.7 NIL 100mg 3 No Complete 0.9 NO 
5 Dhanalaksh
mi 
45y F A L 3.8 HTN Inferior 
calyx 
42 0.8 NIL 100mg 3 No Complete 1 NO 
6 Ramalingam 65y M A R 3.5 DM/HTN Inferior 
calyx 
40 1 NIL 200mg 6 uro sepsis Complete 1.8 NO 
7 Latha 35y F A R 3 NO Inferior 
calyx 
35 0.7 NIL 100mg 3 No Complete 0.8 NO 
8 Rajendran 44y M A L 3.3 NO Inferior 
calyx 
37 0.8 NIL 150mg 5 bleeding Complete 0.9 NO 
9 Dhanalaksh
mi 
55y F A L 2.9 NO Middle 
calyx 
39 0.8 NIL 150mg 3 No Complete 0.7 NO 
10 Maryappan 45y M A L 2.4 HTN Inferior 
calyx 
45 0.9 NIL 100mg 3 No Complete 1 NO 
11 Vijay kumar 28y M A R-L U 3.7 NO Inferior 
calyx 
50 1.5 1 150mg 3 No Complete 0.8 L-URS 
12 Kaviyamuth
an 
30y M A L 2.7 NO Inferior 
calyx 
49 0.6 NIL 100mg 3 No Complete 0.7 NO 
13 Mahendran 43y M A L 2.9 NO Inferior 
calyx 
47 0.7 NIL 100mg 3 No Complete 0.9 NO 
14 Lakshmi 45y F A L-B/L 3 NO Middle 
calyx 
50 0.9 NIL 100mg 3 No Complete 0.6 NO 
15 Vijay kumar 35y M A R 3.3 NO Middle 
calyx 
47 0.5 NIL 150mg 3 No Incomplete 0.8 ESWL 
  
16 Mahesh 34y M A L 3 NO Superior 
calyx 
41 0.3 NIL 200mg 4 uro sepsis Complete 0.7 NO 
17 Kalidoss 19y M A R 2.7 NO Inferior 
calyx 
45 0.7 NIL 100mg 3 No Complete 0.9 NO 
18 Bharath 20y M A R 2.9 NO Inferior 
calyx 
38 0.5 NIL 100mg 3 No Complete 0.8 NO 
19 Seetha 24y F A L 3.1 NO Inferior 
calyx 
39 0.8 NIL 100mg 3 No Complete 0.7 NO 
20 Saroja 45y F A R 3.2 DM Middle 
calyx 
40 0.6 NIL 150mg 5 uro sepsis Complete 0.9 NO 
21 Krisnaveni 40y F A L 3.3 HTN Superior 
calyx 
44 0.4 NIL 100mg 3 No Complete 1 NO 
22 Lakshmi 45y F A R-B/L 3.4 NO Superior 
calyx 
39 0.9 NIL 100mg 3 No Complete 0.8 NO 
23 Kannan 45y M A R 2.1 DM Inferior 
calyx 
45 0.8 NIL 150mg 4 No Complete 2 NO 
24 Thenarasu 20
Y 
M A R 3.7 NO Inferior 
calyx 
38 0.5 NIL 100mg 3 No Incomplete 0.8 NO 
25 Jennifer 24
Y 
F A L-B/L 2.8 NO Inferior 
calyx 
46 0.7 NIL 100mg 3 No Complete 0.9 NO 
26 Thangarasu 28y M A L 2.9 NO Inferior 
calyx 
52 0.8 NIL 100mg 3 No Complete 0.7 NO 
27 Arun kumar 23y M A L 2.5 NO Inferior 
calyx 
53 0.3 NIL 150mg 3 No Complete 0.9 NO 
28 Vijay raj 43y M A R-R 
VUJ 
3 NO Middle 
calyx 
49 0.6 NIL 150mg 3 No Complete 0.8 R-URS 
29 Rajan 43y M A R 3.2 DM Inferior 
calyx 
52 1.5 1 100mg 3 No Complete 0.8 NO 
30 Jennifer 24y F A R-B/L 3.5 NO Inferior 
calyx 
56 0.5 NIL 150mg 3 No Complete 0.9 NO 
31 Erullappan 31y M A L 3.6 NO Inferior 
calyx 
49 0.8 NIL 100mg 3 No Complete 0.8 NO 
32 Arun  23y M A L 3.7 NO Inferior 
calyx 
50 0.7 NIL 150mg 3 No Complete 0.7 NO 
33 Poongodi 27y M A R 2.9 NO Superior 
calyx 
48 0.9 NIL 100mg 3 No Complete 0.6 NO 
34 Devammal 45y F A L-B/L 2.8 DM/HTN Inferior 
calyx 
47 0.6 NIL 100mg 4 No Complete 0.9 NO 
35 Tameem 
ansari 
25y M A R 2.7 NO Inferior 
calyx 
49 0.7 NIL 200mg 6 uro sepsis Complete 1 PCN 
36 Poongodai 29y F A R 2.5 NO Superior 
calyx 
48 0.9 NIL 100mg 3 No Complete 0.9 NO 
37 Shiva nathan 61y M A R 2.4 HTN Inferior 53 0.8 NIL 150mg 5 uro sepsis Complete 1.3 NO 
  
calyx 
38 Vijaya 46y F A R 3.6 NO Inferior 
calyx 
55 0.6 NIL 100mg 3 No Complete 1.8 NO 
39 Palani 65y M A L 2.9 NO Inferior 
calyx 
57 0.5 NIL 100mg 3 No Complete 1.9 NO 
40 Settu 45y M A R 3.5 DM Middle 
calyx 
53 0.7 NIL 150mg 4 No Complete 0.8 NO 
41 Sakthi vel 23y M A R 3.4 NO Inferior 
calyx 
48 0.6 NIL 100mg 3 No Complete 0.7 NO 
42 Chidambara
m 
25y M A R 2.3 NO Inferior 
calyx 
47 0.8 NIL 100mg 3 No Complete 0.6 NO 
43 Paripoorana
m 
47y F A L 3.2 NO Inferior 
calyx 
46 0.7 NIL 100mg 3 No Complete 0.9 NO 
44 Thanika 
chalam 
45y M A R 3.3 HTN Middle 
calyx 
45 0.7 NIL 150mg 3 No Complete 0.8 NO 
45 Thirumurug
an 
35y M A L 3.7 NO Inferior 
calyx 
49 0.8 NIL 100mg 3 No Incomplete 0.7 ESWL 
46 Thanika 
chalam 
40
Y 
M A L 2.5 NO Inferior 
calyx 
51 0.9 NIL 100mg 3 No Complete 0.6 NO 
47 Partheban 45y M A L 2.4 DM Inferior 
calyx 
54 0.8 NIL 100mg 3 No Complete 0.9 NO 
48 Parama 
sivam 
40 
y  
M A L 2.1 NO Inferior 
calyx 
56 0.4 NIL 150mg 3 No Complete 0.8 NO 
49 Kaliyyamma
l 
65y F A L 2 DM Middle 
calyx 
53 0.3 NIL 100mg 3 No Complete 1.1 NO 
50 Devamani 45y F A L-B/L 2.9 NO Middle 
calyx 
49 1.3 1 150mg 3 No Complete 1 NO 
51 Anbalagan 40y M B R 2.8 NO Inferior 
calyx 
39 0.5 NIL 150mg 4 No Complete 0.8 NO 
52 Chidambara
m 
25
Y 
M B L-R U 3 NO Inferior 
calyx 
45 0.6 NIL 150mg 4 No Complete 0.7 R-URS 
53 Maiyam 
beevi 
50y F B R 3.3 DM Inferior 
calyx 
57 0.7 NIL 200mg 5 uro sepsis Complete 0.8 NO 
54 Viji 30y F B L 3.9 NO Inferior 
calyx 
55 0.8 NIL 150mg 4 No Complete 0.9 NO 
55 Govinda 
rajan 
43y M B R-L U 4 NO Middle 
calyx 
53 0.9 NIL 150mg 4 No Complete 0.6 L-URS 
56 Dayalan 43y M B R 3.8 NO Inferior 
calyx 
54 0.8 NIL 150mg 4 No Complete 0.9 NO 
57 Syed 60y M B R 3.6 DM/HTN Inferior 
calyx 
52 0.4 NIL 200mg 5 bleeding Complete 2 NO 
58 Agnesh 55y M B L 3.6 NO Inferior 
calyx 
49 0.8 NIL 150mg 4 No Complete 0.7 NO 
  
59 Parameswari 49y F B R 3.2 DM Inferior 
calyx 
47 0.9 NIL 150mg 4 No Complete 0.8 NO 
60 Raja 
mohamed 
28y M B R-RU 3 NO Inferior 
calyx 
45 0.3 NIL 150mg 4 No Complete 0.9 R-URS 
61 Ganesh 46y M B R 2.9 NO Middle 
calyx 
49 1.5 2 150mg 4 No Complete 0.8 NO 
62 Murugan 30y M B B/L-L 
U 
3.3 NO Inferior 
calyx 
50 0.6 NIL 150mg 4 No Incomplete 0.9 NO 
63 Saratha 40y F B R-L U 3.6 HTN Inferior 
calyx 
53 0.8 NIL 150mg 4 No Complete 1.2 L-URS 
64 Sarathamma
l 
47y F B R 3.7 NO Inferior 
calyx 
52 0.7 NIL 150mg 4 No Complete 1 NO 
65 Nalini 24y F B R 3.8 NO Middle 
calyx 
44 0.5 NIL 150mg 4 No Complete 0.9 NO 
66 Srinivasan 19y M B L-R U 3.5 NO Inferior 
calyx 
45 0.7 NIL 150mg 4 No Complete 0.8 R-URS 
67 Vasudevan 45y M B R 3.4 DM Inferior 
calyx 
46 0.8 NIL 250mg 5 uro sepsis Complete 1.5 NO 
68 Navneethu 39y M B R 2.9 NO Inferior 
calyx 
59 0.5 NIL 200mg 4 No Incomplete 0.6 ESWL 
69 Natarajan 65y M B L 2.3 HTN Middle 
calyx 
60 0.8 NIL 250mg 4 No Complete 1.2 NO 
70 Malliga 43y F B L 2.2 NO Inferior 
calyx 
47 0.4 NIL 200mg 4 No Complete 0.8 NO 
71 Palani 40y M B L 2.6 NO Inferior 
calyx 
46 0.8 NIL 200mg 4 No Complete 0.7 NO 
72 Ravi kumar 49y M B L 2.7 DM Superior 
calyx 
45 0.9 NIL 150mg 4 No Complete 0.9 NO 
73 Praveen 29y M B L 2.9 NO Inferior 
calyx 
53 0.6 NIL 150mg 4 No Complete 0.7 NO 
74 Dayalan 37y M B R 3 NO Inferior 
calyx 
55 0.7 NIL 200mg 4 No Complete 0.9 NO 
75 Govindamm
al 
35y F B L-B/L 2.2 NO Inferior 
calyx 
58 0.9 NIL 150mg 4 No Complete 0.7 NO 
76 Kowsalya 18y F B L 2.8 NO Superior 
calyx 
59 0.5 NIL 150mg 4 No Complete 0.8 NO 
77 Sasikala 18y F B L 3.1 NO Inferior 
calyx 
52 0.3 NIL 200mg 4 No Incomplete 0.6 ESWL 
78 Krisnaveni 60y F B R 3.2 DM/HTN Inferior 
calyx 
51 0.8 NIL 250mg 6 uro sepsis Complete 1.8 NO 
79 Senbagavalli 21y F B R 2.9 NO Inferior 
calyx 
49 0.8 NIL 200mg 4 No Complete 0.8 NO 
80 Murali 25y M B R 3 NO Middle 48 0.9 NIL 150mg 4 No Complete 0.7 NO 
  
calyx 
81 Shymala 21y M B L 2.7 NO Inferior 
calyx 
44 1.5 1 150mg 4 No Complete 0.9 NO 
82 Prabagaran 36y M B R 2.9 NO Inferior 
calyx 
42 0.6 NIL 150mg 4 No Complete 1 NO 
83 Subramani 33y M B L-B/L 2.7 NO Inferior 
calyx 
41 0.4 NIL 150mg 4 No Complete 0.8 NO 
84 Palani 45y M B R 2.8 NO Superior 
calyx 
40 1.4 1 150mg 4 No Complete 0.9 NO 
85 Subhu 38y F B L 2.6 NO Inferior 
calyx 
39 0.7 NIL 200mg 4 No Complete 0.7 NO 
86 Munusamy 52y M B R 2.4 HTN Inferior 
calyx 
51 0.6 NIL 200mg 5 uro sepsis Complete 0.9 NO 
87 Thangarasu 38y M B R 3.3 NO Inferior 
calyx 
53 0.9 NIL 150mg 4 No Complete 1 NO 
88 Vinayagam 40y M B R 3.4 DM Middle 
calyx 
54 1.7 2 250mg 5 uro sepsis Complete 1.6 NO 
89 Lalitha 50y F B R 3.9 DM Inferior 
calyx 
62 0.6 NIL 150mg 4 No Complete 1.4 NO 
90 Sivalingam 70y M B L 3.8 DM Inferior 
calyx 
53 0.7 NIL 150mg 4 No Complete 1.2 NO 
91 Munusamy 47y M B L 3.1 NO Superior 
calyx 
51 0.5 NIL 150mg 4 No Complete 0.7 NO 
92 Kaliyarasu 35y M B L 3 NO Inferior 
calyx 
52 1.2 1 150mg 4 No Complete 0.7 NO 
93 Prabhakaran 25y M B R 2.9 NO Inferior 
calyx 
51 0.8 NIL 150mg 4 No Complete 0.8 NO 
94 Govinda raj 55y M B L 2.5 DM Inferior 
calyx 
49 0.9 NIL 150mg 4 No Complete 0.9 NO 
95 Kaleeshwari 38y F B R 3.5 NO Middle 
calyx 
48 0.5 NIL 200mg 4 No Complete 0.7 NO 
96 Govindamm
al 
35y F B R-B/L 3.4 NO Inferior 
calyx 
47 0.4 NIL 150mg 4 No Complete 0.8 NO 
97 Anjammal 50y F B L 2.8 HTN Inferior 
calyx 
43 1.2 1 150mg 5 bleeding Complete 1.3 NO 
98 Balaji 46y M B R 2.7 NO Inferior 
calyx 
42 0.9 NIL 200mg 4 No Complete 0.7 NO 
99 Sathya 53y F B L 3 DM Inferior 
calyx 
44 0.7 NIL 150mg 4 No Complete 0.7 NO 
100 Subramani 33y M B R-B/L 2.8 NO Middle 
calyx 
45 0.6 NIL 150mg 4 No Complete 0.9 NO 
    
  
APPENDIX 5 
                                        ABBREVIATIONS 
PCNL- Percutaneous nephrolithotomy 
PCN- Percutaneous nephrostomy 
IVP- Intravenous pyelogram 
CECT- Contrast enhanced computed tomography 
DM-  Diabetes mell itus 
 
  
  
  
  
 
